PL377476A1 - Oznaczanie CVD - Google Patents

Oznaczanie CVD

Info

Publication number
PL377476A1
PL377476A1 PL377476A PL37747603A PL377476A1 PL 377476 A1 PL377476 A1 PL 377476A1 PL 377476 A PL377476 A PL 377476A PL 37747603 A PL37747603 A PL 37747603A PL 377476 A1 PL377476 A1 PL 377476A1
Authority
PL
Poland
Prior art keywords
calprotectin
antibody
assay
cvd
body fluid
Prior art date
Application number
PL377476A
Other languages
English (en)
Other versions
PL216385B1 (pl
Inventor
Erling Sundrehagen
Original Assignee
Axis-Shield Asa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axis-Shield Asa filed Critical Axis-Shield Asa
Publication of PL377476A1 publication Critical patent/PL377476A1/pl
Publication of PL216385B1 publication Critical patent/PL216385B1/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54346—Nanoparticles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/02—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from eggs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4727—Calcium binding proteins, e.g. calmodulin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Nanotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Optical Head (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Gyroscopes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analyzing Materials By The Use Of Ultrasonic Waves (AREA)
  • Devices For Conveying Motion By Means Of Endless Flexible Members (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
PL377476A 2002-12-20 2003-12-22 Sposób testowania do wykrywania możliwości wystąpienia lub skłonności do choroby niedokrwiennej serca lub udaru PL216385B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0229747.1A GB0229747D0 (en) 2002-12-20 2002-12-20 Assay

Publications (2)

Publication Number Publication Date
PL377476A1 true PL377476A1 (pl) 2006-02-06
PL216385B1 PL216385B1 (pl) 2014-03-31

Family

ID=9950111

Family Applications (2)

Application Number Title Priority Date Filing Date
PL394295A PL394295A1 (pl) 2002-12-20 2003-12-22 Sposób oznaczania kalprotektyny, zestaw do stosowania w tym sposobie, zautomatyzowany aparat oraz sposób diagnozowania choroby
PL377476A PL216385B1 (pl) 2002-12-20 2003-12-22 Sposób testowania do wykrywania możliwości wystąpienia lub skłonności do choroby niedokrwiennej serca lub udaru

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL394295A PL394295A1 (pl) 2002-12-20 2003-12-22 Sposób oznaczania kalprotektyny, zestaw do stosowania w tym sposobie, zautomatyzowany aparat oraz sposób diagnozowania choroby

Country Status (16)

Country Link
US (3) US10101325B2 (pl)
EP (2) EP1573335B1 (pl)
JP (2) JP4653492B2 (pl)
CN (3) CN102608326A (pl)
AT (2) ATE380345T1 (pl)
AU (1) AU2003295142A1 (pl)
CA (2) CA2729365C (pl)
DE (2) DE60317931T2 (pl)
DK (2) DK1739430T3 (pl)
ES (2) ES2323475T3 (pl)
GB (1) GB0229747D0 (pl)
NO (1) NO20052161L (pl)
PL (2) PL394295A1 (pl)
PT (1) PT1573335E (pl)
SI (1) SI1573335T1 (pl)
WO (1) WO2004057341A2 (pl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0229747D0 (en) * 2002-12-20 2003-01-29 Axis Shield Asa Assay
US7659087B2 (en) 2004-07-23 2010-02-09 Aspenbio Pharma, Inc. Methods and devices for diagnosis of appendicitis
ATE494391T1 (de) 2004-07-23 2011-01-15 Aspenbio Pharma Inc Verfahren und vorrichtungen zur diagnose von appendizitis
EP1862805A1 (en) * 2006-06-01 2007-12-05 University of Zürich The use of mrp 8/14 levels for discrimination of individuals at risk of acute coronary syndromes
CA2753886C (en) * 2009-03-02 2018-06-12 Catholic Healthcare West Diagnostic devices and methods of use
AU2010244523B2 (en) * 2009-05-07 2016-09-29 Chreto Aps Method for purification of target polypeptides
US9574977B2 (en) * 2013-02-26 2017-02-21 Innova Prep Liquid to liquid biological particle concentrator with disposable fluid path
EP2511704A1 (en) 2011-04-13 2012-10-17 Immundiagnostik AG Assay method for intrinsic acute kidney injury
NO20110895A1 (no) * 2011-06-21 2012-12-24 Magne Fagerhol Kompetitive S100A9 immunoanalyser
ES2402457B2 (es) * 2011-10-19 2014-01-20 Universidade De Vigo Procedimiento para el diagnóstico de derrame pleural maligno mediante la determinación de la concentración de calprotectina en líquido pleural.
US9122968B2 (en) 2012-04-03 2015-09-01 X-Card Holdings, Llc Information carrying card comprising a cross-linked polymer composition, and method of making the same
US9594999B2 (en) 2012-04-03 2017-03-14 X-Card Holdings, Llc Information carrying card comprising crosslinked polymer composition, and method of making the same
HK1212767A1 (zh) * 2012-09-12 2016-06-17 Berg Llc 標誌物用於識別心臟毒性劑的用途
CN105190651B (zh) 2013-03-15 2019-06-04 X卡控股有限公司 用于制作信息携带卡的芯层的方法以及结果产品
RU2757771C2 (ru) * 2017-02-07 2021-10-21 Люфстоун Ас Биомаркеры для диагностики связанного с имплантом риска повторной операции с имплантом из-за асептического расшатывания
EP3385712A1 (en) 2017-04-03 2018-10-10 Gentian AS Improved calprotectin assay
BR112019023210A2 (pt) 2017-05-09 2020-05-26 Immundiagnostik Ag Método para determinação de membros da família s100 de proteínas de ligação ao cálcio por meio de imunoturbidimetria
CN108196066A (zh) * 2018-01-22 2018-06-22 安徽伊普诺康生物技术股份有限公司 一种测定钙防卫蛋白的试剂盒及其制备使用方法
US11361204B2 (en) 2018-03-07 2022-06-14 X-Card Holdings, Llc Metal card
EP4150337A1 (en) * 2020-05-13 2023-03-22 Nordic Bioscience A/S Calprotectin assay
US20240110864A1 (en) * 2020-09-01 2024-04-04 Oncodea Corporation Predictive diagnostic test for early detection and monitoring of diseases
US12528279B2 (en) 2022-10-20 2026-01-20 X-Card Holdings, Llc Core layer for information carrying card, resulting information carrying card, and methods of making the same
US12220897B2 (en) 2022-10-20 2025-02-11 X-Card Holdings, Llc Core layer for information carrying card, resulting information carrying card, and methods of making the same

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4287202A (en) * 1978-05-26 1981-09-01 Horrobin David F Treatment and/or prophylaxis of spasms of coronary arteries
JPS55162059A (en) * 1979-06-05 1980-12-17 Mochida Pharmaceut Co Ltd Measuring method for antigen, antibody or their complex and measurement reagent kit
US4401765A (en) * 1981-09-01 1983-08-30 E. I. Du Pont De Nemours And Company Covalently bonded high refractive index particle reagents and their use in light scattering immunoassays
US4480042A (en) * 1981-10-28 1984-10-30 E. I. Du Pont De Nemours And Company Covalently bonded high refractive index particle reagents and their use in light scattering immunoassays
GB8318754D0 (en) * 1983-07-11 1983-08-10 Fagerhol M K F Human proteins anti-sera test kits
JPS60139621A (ja) 1983-12-27 1985-07-24 Grelan Pharmaceut Co Ltd 抗血栓剤
JPS625970A (ja) 1985-03-15 1987-01-12 Terumo Corp ピラジン誘導体およびこれを含有する血小板凝集抑制剤
EP0310361A3 (en) * 1987-09-30 1989-05-24 Beckman Instruments, Inc. Tridentate conjugate and method of use thereof
GB2218100A (en) * 1988-03-02 1989-11-08 Erling Sundrehagen Conjugates for the detection and/or quantification of antigenic substances in body fluids
EP0414223B1 (en) * 1989-08-23 1996-06-26 Canon Kabushiki Kaisha Method for measuring an immunologically active material and apparatus suitable for practising said method
US5455160A (en) * 1993-05-27 1995-10-03 Fagerhol; Magne K. Diagnostic test and kit for disease or disorders in the digestive system
US5776348A (en) * 1995-02-07 1998-07-07 Massachusetts Institute Of Technology Mineral precipitation system and method for inhibiting mineral precipitate formation
AU4790597A (en) 1996-11-01 1998-05-29 Nycomed Pharma As Process for the extraction of proteins
ES2239801T3 (es) * 1997-04-02 2005-10-01 The Brigham And Women's Hospital, Inc. Uso de un agente para disminuir el riesgo de enfermedad cardiovascular.
GB9816088D0 (en) 1998-07-23 1998-09-23 Axis Biochemicals Asa System
JP2002523749A (ja) * 1998-08-20 2002-07-30 アクシス シールド エイエスエイ 心血管疾患のためのアッセイ方法
ATE497171T1 (de) * 1999-07-05 2011-02-15 Leuven K U Res & Dev Von willebrand-faktor-aktivitätsnachweis
EP1212101A1 (en) 1999-08-31 2002-06-12 The Brigham And Women's Hospital, Inc. Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases
FR2800636A1 (fr) * 1999-11-05 2001-05-11 Bio Merieux Particules composites, conjugues derives, leur procede de preparation et utilisations
US7011952B2 (en) * 2000-02-22 2006-03-14 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
US20030059461A1 (en) * 2000-06-06 2003-03-27 Sibtech, Inc. Molecular delivery vehicle for delivery of selected compounds to targets
JP4733335B2 (ja) * 2000-08-29 2011-07-27 協和メデックス株式会社 再現性良好な凝集イムノアッセイ法及び試薬
JP2002318233A (ja) * 2001-04-19 2002-10-31 Shino Test Corp 測定対象物質の比濁法測定試薬及び測定対象物質の比濁法測定方法
EP1322957B1 (en) * 2001-05-04 2009-08-12 Biosite Incorporated Diagnostic markers of acute coronary syndromes and methods of use thereof
GB0229747D0 (en) * 2002-12-20 2003-01-29 Axis Shield Asa Assay
FR2872579B1 (fr) * 2004-06-30 2006-11-24 Pasteur Institut Detection de la tuberculose et de l'infection par mycobacterium tuberculosis a l'aide de hbha
WO2007106781A2 (en) * 2006-03-10 2007-09-20 University Of Rochester Ecg-based differentiation of lqt1 and lqt2 mutation

Also Published As

Publication number Publication date
WO2004057341A2 (en) 2004-07-08
CA2729365C (en) 2018-09-18
US20110318847A1 (en) 2011-12-29
NO20052161D0 (no) 2005-05-03
JP4653492B2 (ja) 2011-03-16
ATE380345T1 (de) 2007-12-15
JP2006510895A (ja) 2006-03-30
DE60317931D1 (en) 2008-01-17
AU2003295142A1 (en) 2004-07-14
US10101325B2 (en) 2018-10-16
CN1729398A (zh) 2006-02-01
CA2729365A1 (en) 2004-07-08
EP1739430A2 (en) 2007-01-03
DE60317931T2 (de) 2008-11-13
CN101893635A (zh) 2010-11-24
CN1729398B (zh) 2012-04-04
DK1739430T3 (da) 2009-07-13
GB0229747D0 (en) 2003-01-29
EP1739430B1 (en) 2009-04-01
DE60327007D1 (de) 2009-05-14
US20190049439A1 (en) 2019-02-14
CA2504876A1 (en) 2004-07-08
CN101893635B (zh) 2014-04-09
JP2010019849A (ja) 2010-01-28
ES2323475T3 (es) 2009-07-16
JP5744385B2 (ja) 2015-07-08
NO20052161L (no) 2005-07-19
EP1573335A2 (en) 2005-09-14
PT1573335E (pt) 2007-12-21
DK1573335T3 (da) 2008-04-14
ES2297250T3 (es) 2008-05-01
EP1739430A3 (en) 2007-01-17
WO2004057341A3 (en) 2004-10-21
PL216385B1 (pl) 2014-03-31
ATE427498T1 (de) 2009-04-15
EP1573335B1 (en) 2007-12-05
SI1573335T1 (sl) 2008-04-30
US20060134705A1 (en) 2006-06-22
CN102608326A (zh) 2012-07-25
PL394295A1 (pl) 2011-09-12

Similar Documents

Publication Publication Date Title
PL377476A1 (pl) Oznaczanie CVD
Liu et al. Graphene oxide functionalized long period grating for ultrasensitive label-free immunosensing
WO2007011936A3 (en) Lateral flow assay and device using magnetic particles
Sha et al. A one-step electrochemiluminescence immunosensor preparation for ultrasensitive detection of carbohydrate antigen 19-9 based on multi-functionalized graphene oxide
MY162697A (en) Methods, devices and kits for detecting or monitoring acute kidney injury
EP2538218A8 (en) Biochemical markers for CVD risk assessment
ATE358274T1 (de) Diagnostisches testverfahren
WO2009117510A3 (en) Multi-wavelength analyses of sol-particle specific binding assays
SG169395A1 (en) Detection of cancer by elevated levels of bcl-2
WO2008063770A3 (en) Reducing optical interference in a fluidic device
DE602007010032D1 (de) Immunoassay mit mehreren analyten
WO2006047591A3 (en) Rapid microfluidic assay for analyte interactions
Orlov et al. Development of immunoassays using interferometric real-time registration of their kinetics
Belicky et al. Full-length antibodies versus single-chain antibody fragments for a selective impedimetric lectin-based glycoprofiling of prostate specific antigen
WO2008067008A3 (en) A method for the quantitative evaluation of sex hormones in a serum sample
Choi et al. Reflectometric interference spectroscopy-based immunosensing using immobilized antibody via His-tagged recombinant protein A
CA2434694A1 (en) Detection and quantification of cripto-1
DE602006014120D1 (de) Kolloidale metallkonjugate
NO20052553D0 (no) Cobalaminanalyse.
ATE520985T1 (de) Verfahren zur bestimmung von antigen und antikörper gegen das antigen
WO2018226098A3 (en) METHODS OF TYPING NEUROLOGICAL DISORDERS AND CANCER, AND DEVICES THEREOF
WO2005031365A3 (en) Rapid determination of hepatocyte growth factor (hgf) in the body fluids
Li et al. Flow sandwich immunoassay for specific anti-OVA IgG antibody by use of surface plasmon resonance sensor
Noah et al. Immunosensors for quantifying cyclooxygenase 2 pain biomarkers
JP2011516840A5 (pl)

Legal Events

Date Code Title Description
VDSO Invalidation of derivated patent or utility model

Ref document number: 394295

Country of ref document: PL

Kind code of ref document: A1

RECP Rectifications of patent specification